Abbott Labs files suit against Impax over Simcor patent challenge; Ranbaxy debuts generic Aricept in USA

29 November 2010

US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirmed that it has initiated a challenge of patents listed in connection with the cholesterol lowerer Simcor (niacin/simvastatin) extended-release tablets, 1000/20mg.

Impax filed its Abbreviated New Drug Application containing a paragraph IV certification for a generic version of Simcor (niacin/simvastatin) with the US Food & Drug Administration. Following receipt of the notice from the FDA that the ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner - Abbott Laboratories (NYSE: ABT) - of its paragraph IV certification.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical